Aligos Therapeutics(US:ALGS) Globenewswire·2025-05-06 12:00Core Insights - Aligos Therapeutics is advancing its clinical development plans for therapies targeting liver and viral diseases, having raised over $100 million for its Phase 2 study of ALG-000184 in chronic hepatitis B virus infection [2][3] - The company reported significant financial progress, with a net income of $43.1 million for Q1 2025, a substantial improvement from a net loss of $34.9 million in Q1 2024 [7][10] Recent Business Progress - Aligos is on track to begin dosing for the Phase 2 study of ALG-000184 by mid-2025, following positive FDA correspondence [2] - Data presented at the APASL meeting indicated that ALG-000184 has the potential to be a first-line treatment for chronic HBV infection, with a well-tolerated profile and promising antiviral activity [5][12] - The Phase 2 B-SUPREME study will evaluate ALG-000184 against tenofovir disoproxil fumarate in approximately 200 untreated adult subjects with chronic HBV infection [5] Pipeline Updates - ALG-000184 is positioned as a potential first-/best-in-class small molecule for chronic hepatitis B virus infection [3] - ALG-055009, a THR-β agonist for metabolic dysfunction-associated steatohepatitis (MASH), has shown best-in-class potential, with significant reductions in liver fat observed in clinical trials [4][12] - The company is in discussions for potential partnerships regarding ALG-055009 with multinational pharmaceutical companies [2] Financial Results for Q1 2025 - Cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2025, compared to $56.9 million at the end of 2024, providing sufficient funding into the second half of 2026 [6] - Research and development expenses decreased to $14.5 million from $16.4 million year-over-year, primarily due to reduced third-party clinical trial expenses [8] - General and administrative expenses also decreased to $5.1 million from $6.7 million, reflecting lower third-party costs [9]